Bayer (BAYN GY) executive says no change to 2026 guidance due to US pharmaceutical tariffs announced last week

Bayer's reaffirmation of its 2026 guidance in light of the newly imposed US pharmaceutical tariffs indicates confidence in its business resilience despite external pressures.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Fed's Goolsbee on says it can be contentious around the Fed policysetting table

KKR (KKR) said to be in talks to sell BMC Helix to Montagu for USD 900mln

Bayer (BAYN GY) executive says no change to 2026 guidance due to US pharmaceutical tariffs announced last week

Dallas Fed Research finds Strait of Hormuz closure could sharply raise inflation; "Little evidence of higher gasoline prices being passed through to core inflation or long-run inflation expectations becoming unanchored", researchers said

Iran's UN ambassador says UN Secretary General's personal envoy currently on route to Tehran to pursue consolations

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This stability can lead to a more favorable sentiment among investors, potentially enhancing Bayer's stock price and bolstering its standing within the pharmaceuticals sector. Observing how other companies in the sector respond to similar headwinds could also provide insight into broader market implications.

Related headlines

The whole workspace, free to try.

Try it free